Stockreport

Nektar Therapeutics: 'Strong Buy' On REZPEG POC Established In AD/AA And Late-Stage Development [Seeking Alpha]

Nektar Therapeutics  (NKTR) 
Last nektar therapeutics earnings: 2/27 04:15 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.nektar.com/investor-relations
PDF Company's REZPEG demonstrated durable efficacy, with SALT Score =20 rates rising to 27.6% at 52 weeks in severe-to-very-severe AA patients. Multiple near-term catalys [Read more]